Showing results 1 to 4 of 4
Title | Author(s) | Issue Date | |
---|---|---|---|
2021 | |||
Atherosclerotic cardiovascular disease risk profile of patients with chronic hepatitis B treated with tenofovir alafenamide or tenofovir disoproxil fumarate for 96 weeks Journal:Alimentary Pharmacology and Therapeutics | 31-Oct-2023 | ||
RETRACTION: Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection Journal:Clinical Gastroenterology and Hepatology | 2018 | ||
Review: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data Journal:Alimentary Pharmacology & Therapeutics | 2022 |